Sponsored Links
| Idera Pharmaceuticals Announces Preliminary Data From Phase 1 Clinical Trial Of IMO-2125 In Treatment-Naive Genotype 1 HCV Patients |
 |
 |
 |
| Medical News - Liver Disease and Hepatitis | |||
|
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) have announced preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naive patients with genotype 1 chronic hepatitis C virus (HCV) infection... Read more: Liver Disease / Hepatitis News From Medical News Today
|